Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) Sees Significant Increase in Short Interest

Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) was the recipient of a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 44,400 shares, a growth of 88.9% from the May 30th total of 23,500 shares. Currently, 1.9% of the company’s shares are short sold. Based on an average daily volume of 10,800 shares, the days-to-cover ratio is currently 4.1 days.

Shares of Entasis Therapeutics stock traded up $0.02 during midday trading on Thursday, reaching $6.35. 1,300 shares of the company’s stock traded hands, compared to its average volume of 10,540. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.79 and a current ratio of 8.79. The company has a market capitalization of $83.91 million and a P/E ratio of -0.52. The company’s 50 day moving average is $6.24. Entasis Therapeutics has a 12 month low of $3.97 and a 12 month high of $13.70.

Entasis Therapeutics (NASDAQ:ETTX) last announced its earnings results on Tuesday, May 14th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.24). Research analysts anticipate that Entasis Therapeutics will post -3.39 EPS for the current year.



An institutional investor recently bought a new position in Entasis Therapeutics stock. BlackRock Inc. acquired a new position in Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 13,755 shares of the company’s stock, valued at approximately $56,000. BlackRock Inc. owned approximately 0.11% of Entasis Therapeutics at the end of the most recent quarter. Institutional investors own 65.02% of the company’s stock.

ETTX has been the subject of several recent research reports. Wedbush reiterated an “outperform” rating and issued a $19.00 price objective on shares of Entasis Therapeutics in a research report on Tuesday, April 2nd. Zacks Investment Research downgraded GreenTree Hospitality Group from a “buy” rating to a “hold” rating in a research report on Monday, May 20th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Entasis Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $16.50.

Entasis Therapeutics Company Profile

Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.

Read More: How to execute a trade ex-dividend strategy?

Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.